Note dell’episodio
Another incremental week for acromegaly research, led by evidence that upper-limb joint damage is nearly universal in patients and an early AI voice test for diagnosis, while rare disease industry news was dominated by deal-making (Lilly's up-to-$1.5B Calytrix buyout, argenx's Unnatural Products acquisition), a positive pivotal hepatitis delta readout from Vir, and Novo's sickle cell filing.

